FSP1 oxidizes NADPH to suppress ferroptosis

Sitao Zhang,Shengsong Gou,Qian Zhang,Xin Yong,Boyi Gan,Da Jia

DOI: https://doi.org/10.1038/s41422-023-00879-z

IF: 44.1

2023-09-23

Cell Research

Abstract:Cell Research, Published online: 22 September 2023; doi:10.1038/s41422-023-00879-z FSP1 oxidizes NADPH to suppress ferroptosis

cell biology

What problem does this paper attempt to address?

LKB1-AMPK Axis Negatively Regulates Ferroptosis by Inhibiting Fatty Acid Synthesis

Changzhi Li,Xuan Dong,Wenjing Du,Xin Shi,Kangjie Chen,Wei Zhang,Minghui Gao

DOI: https://doi.org/10.1038/s41392-020-00297-2

IF: 39.3

2020-01-01

Signal Transduction and Targeted Therapy

Abstract:Dear Editor, Ferroptosis has emerged as a new programmed cell death modality highly relevant to disease.1 Ferroptosis was initially discovered as an iron-dependent non-apoptotic cell death induced by a serial of ferroptosis-inducing agents(FIN),such as erastin and RSL3.Era st in activates ferroptosis by inhibiting the activity of system Xc-,a cystine-glutamate anti porter,resulting in the depletion of cellular cysteine and glutathione(GSH),thus breaking cellular redox homeostasis.Inactivation of glutathione peroxidase 4(GPX4),an enzyme required to remove the toxic lipid hydroperoxides can induce ferroptosis without the depletion of cellular cysteine and GSH.
FSP1-mediated ferroptosis in cancer: from mechanisms to therapeutic applications

Ran Gao,Jinge Wang,Jingjing Huang,Tong Wang,Lingfeng Guo,Wenlu Liu,Jialu Guan,Desen Liang,Qinghui Meng,Huayang Pan

DOI: https://doi.org/10.1007/s10495-024-01966-1

APOPTOSIS

Abstract:Ferroptosis is a new discovered regulated cell death triggered by the ferrous ion (Fe2+)-dependent accumulation of lipid peroxides associated with cancer and many other diseases. The mechanism of ferroptosis includes oxidation systems (such as enzymatic oxidation and free radical oxidation) and antioxidant systems (such as GSH/GPX4, CoQ10/FSP1, BH4/GCH1 and VKORC1L1/VK). Among them, ferroptosis suppressor protein 1 (FSP1), as a crucial regulatory factor in the antioxidant system, has shown a crucial role in ferroptosis. FSP1 has been well validated to ferroptosis in three ways, and a variety of intracellular factors and drug molecules can alleviate ferroptosis via FSP1, which has been demonstrated to alter the sensitivity and effectiveness of cancer therapies, including chemotherapy, radiotherapy, targeted therapy and immunotherapy. This review aims to provide important frameworks that, bring the regulation of FSP1 mediated ferroptosis into cancer therapies on the basis of existing studies.
Regulation of FSP1 myristoylation by NADPH: A novel mechanism for ferroptosis inhibition

Na Liu,Wei-Long Wu,Xiao-Rui Wan,Jing Wang,Jia-Ni Huang,Yi-Yue Jiang,Yi-Chao Sheng,Jun-Chao Wu,Zhong-Qin Liang,Zheng-Hong Qin,Yan Wang

DOI: https://doi.org/10.1016/j.redox.2024.103176

Abstract:Excitotoxicity is a prevalent pathological event in neurodegenerative diseases. The involvement of ferroptosis in the pathogenesis of excitotoxicity remains elusive. Transcriptome analysis has revealed that cytoplasmic reduced nicotinamide adenine dinucleotide phosphate (NADPH) levels are associated with susceptibility to ferroptosis-inducing compounds. Here we show that exogenous NADPH, besides being reductant, interacts with N-myristoyltransferase 2 (NMT2) and upregulates the N-myristoylated ferroptosis suppressor protein 1 (FSP1). NADPH increases membrane-localized FSP1 and strengthens resistance to ferroptosis. Arg-291 of NMT2 is critical for the NADPH-NMT2-FSP1 axis-mediated suppression of ferroptosis. This study suggests that NMT2 plays a pivotal role by bridging NADPH levels and neuronal susceptibility to ferroptosis. We propose a mechanism by which the NADPH regulates N-myristoylation, which has important implications for ferroptosis and disease treatment.
Structural insight into 6-OH-FAD–dependent activation of hFSP1 for ferroptosis suppression

Hongying Lan,Yu Gao,Ting Hong,Zihan Chang,Zhengyang Zhao,Yanfeng Wang,Feng Wang

DOI: https://doi.org/10.1038/s41421-024-00723-7

IF: 38.079

2024-08-21

Cell Discovery

Abstract:Cell Discovery, Published online: 20 August 2024; doi:10.1038/s41421-024-00723-7 Structural insight into 6-OH-FAD–dependent activation of hFSP1 for ferroptosis suppression

cell biology
Integrated chemical and genetic screens unveil FSP1 mechanisms of ferroptosis regulation

Toshitaka Nakamura,Eikan Mishima,Naoya Yamada,André Santos Dias Mourão,Dietrich Trümbach,Sebastian Doll,Jonas Wanninger,Elena Lytton,Peter Sennhenn,Thamara Nishida Xavier da Silva,José Pedro Friedmann Angeli,Michael Sattler,Bettina Proneth,Marcus Conrad

DOI: https://doi.org/10.1038/s41594-023-01136-y

Abstract:Ferroptosis, marked by iron-dependent lipid peroxidation, may present an Achilles heel for the treatment of cancers. Ferroptosis suppressor protein-1 (FSP1), as the second ferroptosis mainstay, efficiently prevents lipid peroxidation via NAD(P)H-dependent reduction of quinones. Because its molecular mechanisms have remained obscure, we studied numerous FSP1 mutations present in cancer or identified by untargeted random mutagenesis. This mutational analysis elucidates the FAD/NAD(P)H-binding site and proton-transfer function of FSP1, which emerged to be evolutionarily conserved among different NADH quinone reductases. Using random mutagenesis screens, we uncover the mechanism of action of next-generation FSP1 inhibitors. Our studies identify the binding pocket of the first FSP1 inhibitor, iFSP1, and introduce the first species-independent FSP1 inhibitor, targeting the NAD(P)H-binding pocket. Conclusively, our study provides new insights into the molecular functions of FSP1 and enables the rational design of FSP1 inhibitors targeting cancer cells.
Inhibition of FSP1: A new strategy for the treatment of tumors (Review)

Qiangfang Dai,Xiaoli Wei,Jumei Zhao,Die Zhang,Yidan Luo,Yue Yang,Yang Xiang,Xiaolong Liu

DOI: https://doi.org/10.3892/or.2024.8764

Abstract:Ferroptosis, a regulated form of cell death, is intricately linked to iron‑dependent lipid peroxidation. Recent evidence strongly supports the induction of ferroptosis as a promising strategy for treating cancers resistant to conventional therapies. A key player in ferroptosis regulation is ferroptosis suppressor protein 1 (FSP1), which promotes cancer cell resistance by promoting the production of the antioxidant form of coenzyme Q10. Of note, FSP1 confers resistance to ferroptosis independently of the glutathione (GSH) and glutathione peroxidase‑4 pathway. Therefore, targeting FSP1 to weaken its inhibition of ferroptosis may be a viable strategy for treating refractory cancer. This review aims to clarify the molecular mechanisms underlying ferroptosis, the specific pathway by which FSP1 suppresses ferroptosis and the effect of FSP1 inhibitors on cancer cells.
FSP1 is a glutathione-independent ferroptosis suppressor

Sebastian Doll,Florencio Porto Freitas,Ron Shah,Maceler Aldrovandi,Milene Costa da Silva,Irina Ingold,Andrea Goya Grocin,Thamara Nishida Xavier da Silva,Elena Panzilius,Christina H. Scheel,André Mourão,Katalin Buday,Mami Sato,Jonas Wanninger,Thibaut Vignane,Vaishnavi Mohana,Markus Rehberg,Andrew Flatley,Aloys Schepers,Andreas Kurz,Daniel White,Markus Sauer,Michael Sattler,Edward William Tate,Werner Schmitz,Almut Schulze,Valerie O’Donnell,Bettina Proneth,Grzegorz M. Popowicz,Derek A. Pratt,José Pedro Friedmann Angeli,Marcus Conrad

DOI: https://doi.org/10.1038/s41586-019-1707-0

IF: 64.8

2019-10-21

Nature

Abstract:Ferroptosis is an iron-dependent form of necrotic cell death marked by oxidative damage to phospholipids1,2. To date, ferroptosis has been believed to be restrained only by the phospholipid hydroperoxide (PLOOH)-reducing enzyme glutathione peroxidase 4 (GPX4)3,4 and radical-trapping antioxidants (RTAs)5,6. The factors which underlie a given cell type's sensitivity to ferroptosis7 are, however, critical to understand the pathophysiological role of ferroptosis and how it may be exploited for cancer treatment. Although metabolic constraints8 and phospholipid composition9,10 contribute to ferroptosis sensitivity, no cell-autonomous mechanisms have been yet been identified that account for ferroptosis resistance. We undertook an expression cloning approach to identify genes able to complement GPX4 loss. These efforts uncovered the flavoprotein "apoptosis inducing factor mitochondria-associated 2 (AIFM2)" as a previously unrecognized anti-ferroptotic gene. AIFM2, hereafter renamed "ferroptosis-suppressor-protein 1" (FSP1), initially described as a pro-apoptotic gene11, confers an unprecedented protection against ferroptosis elicited by GPX4 deletion. We further demonstrate that ferroptosis suppression by FSP1 is mediated via ubiquinone (CoQ10): its reduced form ubiquinol traps lipid peroxyl radicals that mediate lipid peroxidation, while FSP1 catalyses its regeneration by using NAD(P)H. Pharmacological targeting of FSP1 strongly synergizes with GPX4 inhibitors to trigger ferroptosis in a number of cancer entities. In conclusion, FSP1/CoQ10/NAD(P)H exists as a stand-alone parallel system, which co-operates with GPX4 and glutathione (GSH) to suppress phospholipid peroxidation (pLPO) and ferroptosis.

multidisciplinary sciences
Structural insights into FSP1 catalysis and ferroptosis inhibition

Yun Lv,Chunhui Liang,Qichao Sun,Jing Zhu,Haiyan Xu,Xiaoqing Li,Yao-yao Li,Qihai Wang,Huiqing Yuan,Bo Chu,Deyu Zhu

DOI: https://doi.org/10.1038/s41467-023-41626-7

IF: 16.6

2023-09-23

Nature Communications

Abstract:Ferroptosis suppressor protein 1 (FSP1, also known as AIMF2, AMID or PRG3) is a recently identified glutathione-independent ferroptosis suppressor 1,2,3 , but its underlying structural mechanism remains unknown. Here we report the crystal structures of Gallus gallus FSP1 in its substrate-free and ubiquinone-bound forms. The structures reveal a FAD-binding domain and a NAD(P)H-binding domain, both of which are shared with AIF and NADH oxidoreductases 4,5,6,7,8,9 , and a characteristic carboxy-terminal domain as well. We demonstrate that the carboxy-terminal domain is crucial for the catalytic activity and ferroptosis inhibition of FSP1 by mediating the functional dimerization of FSP1, and the formation of two active sites located on two sides of FAD, which are responsible for ubiquinone reduction and a unique FAD hydroxylation respectively. We also identify that FSP1 can catalyze the production of H 2 O 2 and the conversion of FAD to 6-hydroxy-FAD in the presence of oxygen and NAD(P)H in vitro, and 6-hydroxy-FAD directly inhibits ferroptosis in cells. Together, these findings further our understanding on the catalytic and ferroptosis suppression mechanisms of FSP1 and establish 6-hydroxy-FAD as an active cofactor in FSP1 and a potent radical-trapping antioxidant in ferroptosis inhibition.

multidisciplinary sciences
The crystal structure of human ferroptosis suppressive protein 1 in complex with flavin adenine dinucleotide and nicotinamide adenine nucleotide

Shijian Feng,Xiaofang Huang,Dan Tang,Xiaoyu Liu,Liang Ouyang,Dehua Yang,Kunjie Wang,Banghua Liao,Shiqian Qi

DOI: https://doi.org/10.1002/mco2.479

2024-02-28

MedComm

Abstract:The structural section of hFSP1 is shown. The substrate clamp, NADH, and FAD are highlighted. Y296 and F360 comprise the substrate clamp of hFSP1. The clamp is highlighted using text. The NADH and FAD are shown in sticks and colored as green and magenta, respectively. Ferroptosis is a recently discovered form of regulated cell death characterized by its distinct dependence on iron and the peroxidation of lipids within cellular membranes. Ferroptosis plays a crucial role in physiological and pathological situations and has attracted the attention of numerous scientists. Ferroptosis suppressive protein 1 (FSP1) is one of the main regulators that negatively regulates ferroptosis through the GPX4‐independent FSP1–CoQ10–NAD(P)H axis and is a potential therapeutic target for ferroptosis‐related diseases. However, the crystal structure of FSP1 has not been resolved, which hinders the development of therapeutic strategies targeting FSP1. To unravel this puzzle, we purified the human FSP1 (hFSP1) protein using the baculovirus eukaryotic cell expression system and solved its crystal structure at a resolution of 1.75 Å. Furthermore, we evaluated the oxidoreductase activity of hFSP1 with NADH as the substrate and identified E156 as the key amino acid in maintaining hFSP1 activity. Interestingly, our results indicated that hFSP1 exists and functions in a monomeric state. Mutagenesis analysis revealed the critical role of the C‐terminal domain in the binding of substrate. These findings significantly enhance our understanding of the functional mechanism of FSP1 and provide a precise model for further drug development.
FSP1 confers ferroptosis resistance in KEAP1 mutant non-small cell lung carcinoma in NRF2-dependent and -independent manner

Jong Woo Kim,Min-Ju Kim,Tae-Hee Han,Ji-Yoon Lee,Sangok Kim,Hyerin Kim,Kyoung-Jin Oh,Won Kon Kim,Baek-Soo Han,Kwang-Hee Bae,Hyun Seung Ban,Soo Han Bae,Sang Chul Lee,Haeseung Lee,Eun-Woo Lee

DOI: https://doi.org/10.1038/s41419-023-06070-x

2023-08-27

Cell Death and Disease

Abstract:Ferroptosis, a type of cell death induced by lipid peroxidation, has emerged as a novel anti-cancer strategy. Cancer cells frequently acquire resistance to ferroptosis. However, the underlying mechanisms are poorly understood. To address this issue, we conducted a thorough investigation of the genomic and transcriptomic data derived from hundreds of human cancer cell lines and primary tissue samples, with a particular focus on non-small cell lung carcinoma (NSCLC). It was observed that mutations in Kelch-like ECH-associated protein 1 ( KEAP1 ) and subsequent nuclear factor erythroid 2-related factor 2 (NRF2, also known as NFE2L2) activation are strongly associated with ferroptosis resistance in NSCLC. Additionally, AIFM2 gene, which encodes ferroptosis suppressor protein 1 (FSP1), was identified as the gene most significantly correlated with ferroptosis resistance, followed by multiple NRF2 targets. We found that inhibition of NRF2 alone was not sufficient to reduce FSP1 protein levels and promote ferroptosis, whereas FSP1 inhibition effectively sensitized KEAP1 -mutant NSCLC cells to ferroptosis. Furthermore, we found that combined inhibition of FSP1 and NRF2 induced ferroptosis more intensely. Our findings imply that FSP1 is a crucial suppressor of ferroptosis whose expression is partially dependent on NRF2 and that synergistically targeting both FSP1 and NRF2 may be a promising strategy for overcoming ferroptosis resistance in cancer.

cell biology
Phase separation of FSP1 promotes ferroptosis

Toshitaka Nakamura,Clara Hipp,André Santos Dias Mourão,Jan Borggräfe,Maceler Aldrovandi,Bernhard Henkelmann,Jonas Wanninger,Eikan Mishima,Elena Lytton,David Emler,Bettina Proneth,Michael Sattler,Marcus Conrad

DOI: https://doi.org/10.1038/s41586-023-06255-6

IF: 64.8

Nature

Abstract:Ferroptosis is evolving as a highly promising approach to combat difficult-to-treat tumour entities including therapy-refractory and dedifferentiating cancers1-3. Recently, ferroptosis suppressor protein-1 (FSP1), along with extramitochondrial ubiquinone or exogenous vitamin K and NAD(P)H/H+ as an electron donor, has been identified as the second ferroptosis-suppressing system, which efficiently prevents lipid peroxidation independently of the cyst(e)ine-glutathione (GSH)-glutathione peroxidase 4 (GPX4) axis4-6. To develop FSP1 inhibitors as next-generation therapeutic ferroptosis inducers, here we performed a small molecule library screen and identified the compound class of 3-phenylquinazolinones (represented by icFSP1) as potent FSP1 inhibitors. We show that icFSP1, unlike iFSP1, the first described on-target FSP1 inhibitor5, does not competitively inhibit FSP1 enzyme activity, but instead triggers subcellular relocalization of FSP1 from the membrane and FSP1 condensation before ferroptosis induction, in synergism with GPX4 inhibition. icFSP1-induced FSP1 condensates show droplet-like properties consistent with phase separation, an emerging and widespread mechanism to modulate biological activity7. N-terminal myristoylation, distinct amino acid residues and intrinsically disordered, low-complexity regions in FSP1 were identified to be essential for FSP1-dependent phase separation in cells and in vitro. We further demonstrate that icFSP1 impairs tumour growth and induces FSP1 condensates in tumours in vivo. Hence, our results suggest that icFSP1 exhibits a unique mechanism of action and synergizes with ferroptosis-inducing agents to potentiate the ferroptotic cell death response, thus providing a rationale for targeting FSP1-dependent phase separation as an efficient anti-cancer therapy.
TRIM21‐Promoted FSP1 Plasma Membrane Translocation Confers Ferroptosis Resistance in Human Cancers

Jun Gong,Yuhui Liu,Wenjia Wang,Ruizhi He,Qilong Xia,Lin Chen,Chunle Zhao,Yang Gao,Yongkang Shi,Yu Bai,Yangwei Liao,Qi Zhang,Feng Zhu,Min Wang,Xu Li,Renyi Qin

DOI: https://doi.org/10.1002/advs.202302318

IF: 15.1

2023-08-18

Advanced Science

Abstract:FSP1 functions as ferroptosis suppressor parallel to GPx4. This study shows that ferroptosis induction promotes TRIM21 expression, as well as K63 ubiquitination and plasma membrane translocation of FSP1. Furthermore, TRIM21 functions as a negative regulator of ferroptosis by promoting K63 ubiquitination of FSP1. Thus, targeting the TRIM21‐FSP1 axis may provide a novel strategy for promoting ferroptosis sensitivity in cancer therapy. Ferroptosis, an iron‐dependent form of regulated cell death driven by excessive accumulation of lipid peroxides, has become a promising strategy in cancer treatment. Cancer cells exploit antioxidant proteins, including Ferroptosis Suppressor Protein 1 (FSP1), to prevent ferroptosis. In this study, it is found that the E3 ubiquitin ligase TRIM21 bound to FSP1 and mediated its ubiquitination on K322 and K366 residues via K63 linkage, which is essential for its membrane translocation and ferroptosis suppression ability. It is further verified the protective role of the TRIM21‐FSP1 axis in RSL3‐induced ferroptosis in cancer cells and a subcutaneous tumor model. Moreover, TRIM21 is highly expressed in multiple gastrointestinal (GI) tumors, and its expression is further stimulated upon ferroptosis induction in cancer cells and the KPC mouse model. In summary, This study identifies TRIM21 as a negative regulator of ferroptosis through K63 ubiquitination of FSP1, which can serve as a therapeutic target to enhance the chemosensitivity of tumors based on ferroptosis induction.

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
Fostered Nrf2 expression antagonizes iron overload and glutathione depletion to promote resistance of neuron-like cells to ferroptosis

Zixuan Liu,Xuying Lv,Erqun Song,Yang Song

DOI: https://doi.org/10.1016/j.taap.2020.115241

IF: 4.46

2020-11-01

Toxicology and Applied Pharmacology

Abstract:Neurological diseases were often characterized by progressive neuronal death, and emerging evidences suggested that ferroptosis may be an active driver of multiple neurodegenerative diseases. However, the mechanisms underlying ferroptosis in neuron cells are unclear. Here, we demonstrated that ferroptotic stimuli caused injury in neuron-like PC12 cells by modulating the expression of proteins involved in iron metabolism and lipid peroxidation at multiple levels, such as altering iron import/export, activating ferritinophagy, and decreasing glutathione (GSH) level. Nuclear factor erythroid 2-related factor 2 (Nrf2) regulates multiple genes involved in ferroptosis, however, its exact role remain elusive. Our mechanistic inquiry revealed that Nrf2 expression enhanced iron storage capacity by increasing ferritin heavy chain 1 (FTH1) expression in PC12 cells. Moreover, Nrf2 alleviated the decrease in GSH level by promoting the expression of genes related to GSH synthesis, including solute carrier family 7 member 11 (SLC7A11) and cysteine ligase (GCL). The contribution of Nrf2 on ferroptosis resistance was further verified by increasing cell tolerance to oxidative stress. Furthermore, Nfe2l2 (Nrf2) knockdown sensitized cells to ferroptotic cell death. Taken together, our findings suggested that iron accumulation caused by altering iron metabolism and the decrease of GSH content are key factors in determining ferroptosis in PC12 cells, and Nrf2 inhibits ferroptosis by combating iron-induced oxidative stress. Our present study provided new clues for the intervention and prevention against ferroptosis-associated neurological diseases.

pharmacology & pharmacy,toxicology
NUPR1 is a critical repressor of ferroptosis

Jiao Liu,Xinxin Song,Feimei Kuang,Qiuhong Zhang,Yangchun Xie,Rui Kang,Guido Kroemer,Daolin Tang

DOI: https://doi.org/10.1038/s41467-021-20904-2

IF: 16.6

2021-01-28

Nature Communications

Abstract:Abstract Ferroptosis is a type of iron-dependent regulated cell death, representing an emerging disease-modulatory mechanism. Transcription factors play multiple roles in ferroptosis, although the key regulator for ferroptosis in iron metabolism remains elusive. Using NanoString technology, we identify NUPR1, a stress-inducible transcription factor, as a driver of ferroptosis resistance. Mechanistically, NUPR1-mediated LCN2 expression blocks ferroptotic cell death through diminishing iron accumulation and subsequent oxidative damage. Consequently, LCN2 depletion mimics NUPR1 deficiency with respect to ferroptosis induction, whereas transfection-enforced re-expression of LCN2 restores resistance to ferroptosis in NUPR1-deficient cells. Pharmacological or genetic blockade of the NUPR1-LCN2 pathway (using NUPR1 shRNA, LCN2 shRNA, pancreas-specific Lcn2 conditional knockout mice , or the small molecule ZZW-115) increases the activity of the ferroptosis inducer erastin and worsens pancreatitis, in suitable mouse models. These findings suggest a link between NUPR1-regulated iron metabolism and ferroptosis susceptibility.

multidisciplinary sciences
Sabotaging the breaks: FSEN1 expands the toolbox of FSP1 inhibitors

Thamara Nishida Xavier da Silva,José Pedro Friedmann Angeli

DOI: https://doi.org/10.1016/j.chembiol.2023.08.015

2023-09-21

Abstract:The report of heightened lipid peroxidation has shone a spotlight on vulnerabilities within challenging cancers. In this context, FSP1 emerges as a pivotal regulator, actively countering the destructive effects of lipid peroxidation. In a groundbreaking development detailed in the latest issue of Cell Chemical Biology, Hendricks et al. unveil FSEN1, a potent inhibitor of FSP1. The discovery of FSEN1 holds tremendous promise as it synergizes with GPX4 inhibitors, in addition to several FDA-approved drugs, amplifying their capacity to induce ferroptosis in resistant cancer cells. This represents a significant stride towards ferroptosis-based strategies in preclinical settings.
NFE2L1-mediated proteasome function protects from ferroptosis

Stefan Kotschi,Anna Jung,Nienke Willemsen,Anahita Ofoghi,Bettina Proneth,Marcus Conrad,Alexander Bartelt

DOI: https://doi.org/10.1016/j.molmet.2022.101436

Abstract:Objective: Ferroptosis continues to emerge as a novel modality of cell death with important therapeutic implications for a variety of diseases, most notably cancer and degenerative diseases. While susceptibility, initiation, and execution of ferroptosis have been linked to reprogramming of cellular lipid metabolism, imbalances in iron-redox homeostasis, and aberrant mitochondrial respiration, the detailed mechanisms of ferroptosis are still insufficiently well understood. Methods and results: Here we show that diminished proteasome function is a new mechanistic feature of ferroptosis. The transcription factor nuclear factor erythroid-2, like-1 (NFE2L1) protects from ferroptosis by sustaining proteasomal activity. In cellular systems, loss of NFE2L1 reduced cellular viability after the induction of both chemically and genetically induced ferroptosis, which was linked to the regulation of proteasomal activity under these conditions. Importantly, this was reproduced in a Sedaghatian-type Spondylometaphyseal Dysplasia (SSMD) patient-derived cell line carrying mutated glutathione peroxidase-4 (GPX4), a critical regulator of ferroptosis. Also, reduced proteasomal activity was associated with ferroptosis in Gpx4-deficient mice. In a mouse model for genetic Nfe2l1 deficiency, we observed brown adipose tissue (BAT) involution, hyperubiquitination of ferroptosis regulators, including the GPX4 pathway, and other hallmarks of ferroptosis. Conclusion: Our data highlight the relevance of the NFE2L1-proteasome pathway in ferroptosis. Manipulation of NFE2L1 activity might enhance ferroptosis-inducing cancer therapies as well as protect from aberrant ferroptosis in neurodegeneration, general metabolism, and beyond.
Understanding the unique mechanism of ferroptosis: a promising therapeutic target

Yuanyuan Kong,Jing Li,Rufeng Lin,Shifeng Lu,Liucheng Rong,Yao Xue,Yongjun Fang

DOI: https://doi.org/10.3389/fcell.2023.1329147

IF: 5.5

2024-03-18

Frontiers in Cell and Developmental Biology

Abstract:Ferroptosis is an iron-dependent form of regulated cell death and is characterized by high concentrations of intracellular lipid peroxide and a redox imbalance in the cells. Ferroptosis shows distinct morphological and biological features compared with other prominent mechanisms of programmed cell death. The distinct characteristics of ferroptosis include the dysfunction of the lipid peroxide repair enzyme glutathione peroxidase 4, the presence of ferrous iron overload, and the lipid peroxidation of polyunsaturated fatty acids. Several other metabolic pathways (including iron, lipid, and amino acid metabolism) and ferritinophagy, as well as transcription factors, can modulate ferroptosis. However, to date, the molecular mechanism of ferroptosis has not been elucidated. This review outlines the discovery, characterization, regulatory mechanisms, and crosstalk of ferroptosis. Further, we have noted the controversial elements in the ferroptosis-related mechanisms. Our inferences may provide a partial reference for developing strategies to regulate ferroptosis.

cell biology,developmental biology
Ferroptosis and its potential as a therapeutic target

Hanshu Yuan,Justin Pratte,Charles Giardina

DOI: https://doi.org/10.1016/j.bcp.2021.114486

Abstract:Ferroptosis is a recently defined form of programmed cell death that is different from apoptosis. It is an iron-dependent programmed cell death and the accumulation of lipid hydroperoxides to lethal levels make ferroptosis distinct. Ferroptosis can be effectively regulated by a number of cellular variables including iron content, amino acid uptake, polyunsaturated fatty acid incorporation, glutathione biosynthesis, and NADPH levels. A number of severe and common degenerative diseases in humans such as Parkinson's disease and Huntington's disease, as well as several acute injury scenarios, such as stroke, intracerebral hemorrhage, traumatic brain injury, and ischemia-reperfusion injury are likely to be linked to ferroptosis. Ferroptosis may play a critical role in tumor-suppression and has been proposed as a potential target for cancer therapy. However, regulating ferroptosis in vivo remains difficult due to a lack of compounds that can effectively activate or repress ferroptosis. Here we review the cellular mechanisms underlying ferroptosis and the pathophysiological circumstances where its regulation could be beneficial.
On the Mechanism of Cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the Role of Lipid Peroxidation in Ferroptotic Cell Death

Omkar Zilka,Ron Shah,Bo Li,José Pedro Friedmann Angeli,Markus Griesser,Marcus Conrad,Derek A. Pratt,José Pedro Friedmann Angeli

DOI: https://doi.org/10.1021/acscentsci.7b00028

IF: 18.2

2017-03-07

ACS Central Science

Abstract:Ferroptosis is a form of regulated necrosis associated with the iron-dependent accumulation of lipid hydroperoxides that may play a key role in the pathogenesis of degenerative diseases in which lipid peroxidation has been implicated. High-throughput screening efforts have identified ferrostatin-1 (Fer-1) and liproxstatin-1 (Lip-1) as potent inhibitors of ferroptosis - an activity that has been ascribed to their ability to slow the accumulation of lipid hydroperoxides. Herein we demonstrate that this activity likely derives from their reactivity as radical-trapping antioxidants (RTAs) rather than their potency as inhibitors of lipoxygenases. Although inhibited autoxidations of styrene revealed that Fer-1 and Lip-1 react roughly 10-fold more slowly with peroxyl radicals than reactions of α-tocopherol (α-TOH), they were significantly more reactive than α-TOH in phosphatidylcholine lipid bilayers - consistent with the greater potency of Fer-1 and Lip-1 relative to α-TOH as inhibitors of ferroptosis. None of Fer-1, Lip-1, and α-TOH inhibited human 15-lipoxygenase-1 (15-LOX-1) overexpressed in HEK-293 cells when assayed at concentrations where they inhibited ferroptosis. These results stand in stark contrast to those obtained with a known 15-LOX-1 inhibitor (PD146176), which was able to inhibit the enzyme at concentrations where it was effective in inhibiting ferroptosis. Given the likelihood that Fer-1 and Lip-1 subvert ferroptosis by inhibiting lipid peroxidation as RTAs, we evaluated the antiferroptotic potential of 1,8-tetrahydronaphthyridinols (hereafter THNs): rationally designed radical-trapping antioxidants of unparalleled reactivity. We show for the first time that the inherent reactivity of the THNs translates to cell culture, where lipophilic THNs were similarly effective to Fer-1 and Lip-1 at subverting ferroptosis induced by either pharmacological or genetic inhibition of the hydroperoxide-detoxifying enzyme Gpx4 in mouse fibroblasts, and glutamate-induced death of mouse hippocampal cells. These results demonstrate that potent RTAs subvert ferroptosis and suggest that lipid peroxidation (autoxidation) may play a central role in the process.

chemistry, multidisciplinary
Targeting Nrf2 to Suppress Ferroptosis and Mitochondrial Dysfunction in Neurodegeneration

Moataz Abdalkader,Riikka Lampinen,Katja M Kanninen,Tarja M Malm,Jeffrey R Liddell

DOI: https://doi.org/10.3389/fnins.2018.00466

2018-07-10

Abstract:Ferroptosis is a newly described form of regulated cell death, distinct from apoptosis, necroptosis and other forms of cell death. Ferroptosis is induced by disruption of glutathione synthesis or inhibition of glutathione peroxidase 4, exacerbated by iron, and prevented by radical scavengers such as ferrostatin-1, liproxstatin-1, and endogenous vitamin E. Ferroptosis terminates with mitochondrial dysfunction and toxic lipid peroxidation. Although conclusive identification of ferroptosis in vivo is challenging, several salient and very well established features of neurodegenerative diseases are consistent with ferroptosis, including lipid peroxidation, mitochondrial disruption and iron dysregulation. Accordingly, interest in the role of ferroptosis in neurodegeneration is escalating and specific evidence is rapidly emerging. One aspect that has thus far received little attention is the antioxidant transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2). This transcription factor regulates hundreds of genes, of which many are either directly or indirectly involved in modulating ferroptosis, including metabolism of glutathione, iron and lipids, and mitochondrial function. This potentially positions Nrf2 as a key deterministic component modulating the onset and outcomes of ferroptotic stress. The minimal direct evidence currently available is consistent with this and indicates that Nrf2 may be critical for protection against ferroptosis. In contrast, abundant evidence demonstrates that enhancing Nrf2 signaling is potently neuroprotective in models of neurodegeneration, although the exact mechanism by which this is achieved is unclear. Further studies are required to determine to extent to which the neuroprotective effects of Nrf2 activation involve the prevention of ferroptosis.

FSP1 oxidizes NADPH to suppress ferroptosis

LKB1-AMPK Axis Negatively Regulates Ferroptosis by Inhibiting Fatty Acid Synthesis

FSP1-mediated ferroptosis in cancer: from mechanisms to therapeutic applications

Regulation of FSP1 myristoylation by NADPH: A novel mechanism for ferroptosis inhibition

Structural insight into 6-OH-FAD–dependent activation of hFSP1 for ferroptosis suppression

Integrated chemical and genetic screens unveil FSP1 mechanisms of ferroptosis regulation

Inhibition of FSP1: A new strategy for the treatment of tumors (Review)

FSP1 is a glutathione-independent ferroptosis suppressor

Structural insights into FSP1 catalysis and ferroptosis inhibition

The crystal structure of human ferroptosis suppressive protein 1 in complex with flavin adenine dinucleotide and nicotinamide adenine nucleotide

FSP1 confers ferroptosis resistance in KEAP1 mutant non-small cell lung carcinoma in NRF2-dependent and -independent manner

Phase separation of FSP1 promotes ferroptosis

TRIM21‐Promoted FSP1 Plasma Membrane Translocation Confers Ferroptosis Resistance in Human Cancers

Fostered Nrf2 expression antagonizes iron overload and glutathione depletion to promote resistance of neuron-like cells to ferroptosis

NUPR1 is a critical repressor of ferroptosis

Sabotaging the breaks: FSEN1 expands the toolbox of FSP1 inhibitors

NFE2L1-mediated proteasome function protects from ferroptosis

Understanding the unique mechanism of ferroptosis: a promising therapeutic target

Ferroptosis and its potential as a therapeutic target

On the Mechanism of Cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the Role of Lipid Peroxidation in Ferroptotic Cell Death

Targeting Nrf2 to Suppress Ferroptosis and Mitochondrial Dysfunction in Neurodegeneration